Aug 04, 2025
CUMBERLAND PHARMACEUTICALS RECEIVES VIZIENT CONTRACT FOR NEW VIBATIV® 4-VIAL STARTER PAK
Jul 29, 2025
CUMBERLAND PHARMACEUTICALS TO ANNOUNCE Q2 2025 FINANCIAL RESULTS & COMPANY UPDATE
Jun 23, 2025
Cumberland Pharmaceuticals Shares Phase 2 FIGHT DMD Trial Results at the Parent Project Muscular Dystrophy Annual Conference
May 13, 2025
CUMBERLAND PHARMACEUTICALS PARTNERS WITH QUREIGHT TO ADVANCE INNOVATIVE IDIOPATHIC PULMONARY FIBROSIS TREATMENT RESEARCH
Feb 25, 2025
CUMBERLAND PHARMACEUTICALS TO ANNOUNCE ANNUAL 2024 FINANCIAL RESULTS
Feb 18, 2025
VIBATIV® RECEIVES MARKETING APPROVAL IN CHINA
Dec 09, 2024
FDA APPROVES ACETADOTE® sNDA
Nov 07, 2024
Cumberland Pharmaceuticals Reports Third Quarter 2024 Financial Results and Company Update
Nov 06, 2024
CUMBERLAND PHARMACEUTICALS RECEIVES FDA ORPHAN DRUG AND RARE PEDIATRIC DISEASE DESIGNATIONS FOR NEW TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY
Nov 05, 2024
New Study Compares Caldolor® (ibuprofen injection) to ketorolac
Oct 31, 2024
CUMBERLAND PHARMACEUTICALS TO ANNOUNCE THIRD QUARTER 2024 FINANCIAL RESULTS
Aug 06, 2024
Cumberland Pharmaceuticals Reports 16% Sequential Revenue Growth in Second Quarter 2024
May 07, 2024
Cumberland Pharmaceuticals Reports First Quarter 2024 Financial Results & Company Update
Apr 30, 2024
CUMBERLAND PHARMACEUTICALS TO ANNOUNCE FIRST QUARTER 2024 FINANCIAL RESULTS
Apr 02, 2024
NEW REPORT SUPPORTS USE OF CALDOLOR® AS A STANDARD OF CARE ACROSS PATIENT POPULATIONS
Mar 05, 2024
Cumberland Pharmaceuticals Reports Annual 2023 Financial Results
Feb 27, 2024
CUMBERLAND PHARMACEUTICALS TO ANNOUNCE ANNUAL 2023 FINANCIAL RESULTS
Nov 17, 2020
Introducing RediTrex®, A New Methotrexate Delivery System
Nov 10, 2020
Cumberland Pharmaceuticals Reports Third Quarter 2020 Financial Results & Company Update
Aug 18, 2020
Newly Published Literature Supports Use Of Caldolor® For Postoperative Pain And Reduction Of Opioid Use